Ranbaxy Labs Q1 net may dip 127% at Rs 159 cr: P Lilladher
Prabhudas Lilladher expects Ranbaxy Laboratories to report a 26.1 percent growth quarter-on-quarter (decline of 127.1 percent year-on-year) in net profit at Rs 158.6 crore.
August 06, 2013 / 17:24 IST
Prabhudas Lilladher has come out with its first quarter (April-June) earnings estimates for the pharmaceutical sector. The brokerage house expects Ranbaxy Laboratories to report a 26.1 percent growth quarter-on-quarter (decline of 127.1 percent year-on-year) in net profit at Rs 158.6 crore.
Revenues are expected to increase by 8 percent Q-o-Q (down 16.3 percent Y-o-Y) to Rs 2,700 crore, according to Prabhudas Lilladher.Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 40.3 percent Q-o-Q (down 47.7 percent Y-o-Y) to Rs 267.4 crore.EBITDA margin or operating profit margin is likely to be at 9.9 percent in June quarter as against 7.6 percent in March quarter and 15.8 percent in a year ago period.Prabhudas Lilladher on Ranbaxy LaboratoriesWe expect 14 percent Y-o-Y growth and 4 percent Q-o-Q growth in core sales of the company in Q2 2013E on the back of favourable currency, traction in Desvenlafaxine (Pristiq) and Absorica in US. Domestic formulation is likely to be decreased by 3 percent on DPCO impact though we expect lower inventory adjustment due to lower sales growth over the past 12-24 months. Ranbaxy received USD 180 million sales in Q2 2012 from one-off sales of Lipitor and Caduet. Core EBITDA margin to be improved to 9.7-9.9 percent in Q2 2013E vs 8 percent in Q2 2012. The company is likely to report forex loss of INR 1.6 billion in Q2 2013E. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
